Successful transition from insulin to sulfonylurea therapy in a patient with monogenic neonatal diabetes owing to a KCNJ11 F333L [corrected] mutation.
作者信息
Philla Katherine Q, Bauer Andrew J, Vogt Karen S, Greeley Siri Atma W
机构信息
Corresponding author: Katherine Q. Philla,
出版信息
Diabetes Care. 2013 Dec;36(12):e201. doi: 10.2337/dc13-1690.
Abstract
摘要
相似文献
1
Successful transition from insulin to sulfonylurea therapy in a patient with monogenic neonatal diabetes owing to a KCNJ11 F333L [corrected] mutation.一名因KCNJ11 F333L[已修正]突变导致单基因新生儿糖尿病的患者成功从胰岛素治疗过渡到磺脲类药物治疗。
Diabetes Care. 2013 Dec;36(12):e201. doi: 10.2337/dc13-1690.
2
Successful sulfonylurea treatment of a neonate with neonatal diabetes mellitus due to a new KCNJ11 mutation.成功用磺酰脲类药物治疗因 KCNJ11 新突变导致的新生儿糖尿病的新生儿。
Diabetes Res Clin Pract. 2011 Jan;91(1):e1-3. doi: 10.1016/j.diabres.2010.09.027. Epub 2010 Nov 5.
3
Sulfonylurea treatment outweighs insulin therapy in short-term metabolic control of patients with permanent neonatal diabetes mellitus due to activating mutations of the KCNJ11 (KIR6.2) gene.对于因KCNJ11（KIR6.2）基因激活突变导致的永久性新生儿糖尿病患者，在短期代谢控制方面，磺脲类药物治疗优于胰岛素治疗。
Diabetologia. 2006 Sep;49(9):2210-3. doi: 10.1007/s00125-006-0329-x. Epub 2006 Jul 1.
4
ATP-sensitive potassium channels--neonatal diabetes mellitus and beyond.ATP敏感性钾通道——新生儿糖尿病及其他情况
N Engl J Med. 2006 Aug 3;355(5):507-10. doi: 10.1056/NEJMe068142.
5
Unsuccessful switch from insulin to sulfonylurea therapy in permanent neonatal diabetes mellitus due to an R201H mutation in the KCNJ11 gene: a case report.因 KCNJ11 基因 R201H 突变导致永久性新生儿糖尿病由胰岛素转换为磺脲类药物治疗失败：病例报告。
Diabetes Res Clin Pract. 2013 Apr;100(1):e1-2. doi: 10.1016/j.diabres.2013.01.016. Epub 2013 Feb 21.
6
Sulfonylurea-responsive diabetes in childhood.儿童磺脲类药物反应性糖尿病
J Pediatr. 2007 May;150(5):553-5. doi: 10.1016/j.jpeds.2007.03.004.
7
First case of neonatal diabetes with KCNJ11 Q52R mutation successfully switched from insulin to sulphonylurea treatment.首例 KCNJ11 Q52R 突变导致的新生儿糖尿病经磺脲类药物成功转换治疗。
J Diabetes Investig. 2017 Sep;8(5):716-719. doi: 10.1111/jdi.12620. Epub 2017 Feb 16.
8
Successful sulfonylurea treatment of an insulin-naïve neonate with diabetes mellitus due to a KCNJ11 mutation.成功使用磺酰脲类药物治疗因 KCNJ11 突变导致的胰岛素初治新生儿糖尿病。
Pediatr Diabetes. 2010 Jun;11(4):286-8. doi: 10.1111/j.1399-5448.2009.00557.x. Epub 2009 Jul 29.
9
Sulfonylurea therapy in two Korean patients with insulin-treated neonatal diabetes due to heterozygous mutations of the KCNJ11 gene encoding Kir6.2.两名韩国患者因编码Kir6.2的KCNJ11基因杂合突变导致胰岛素治疗的新生儿糖尿病，接受磺脲类药物治疗。
J Korean Med Sci. 2007 Aug;22(4):616-20. doi: 10.3346/jkms.2007.22.4.616.
10
Permanent neonatal diabetes by a new mutation in KCNJ11: unsuccessful switch to sulfonylurea.由KCNJ11基因新突变导致的永久性新生儿糖尿病：磺脲类药物转换治疗失败。
Arch Endocrinol Metab. 2015 Dec;59(6):559-61. doi: 10.1590/2359-3997000000076. Epub 2015 Aug 28.
引用本文的文献
1
Based on systematic druggable genome-wide Mendelian randomization identifies therapeutic targets for diabetes.基于系统药物基因组全基因组孟德尔随机化鉴定糖尿病治疗靶点。
Front Endocrinol (Lausanne). 2024 Jun 10;15:1366290. doi: 10.3389/fendo.2024.1366290. eCollection 2024.
2
New insights into K channel gene mutations and neonatal diabetes mellitus.钾通道基因突变与新生儿糖尿病的新见解。
Nat Rev Endocrinol. 2020 Jul;16(7):378-393. doi: 10.1038/s41574-020-0351-y. Epub 2020 May 6.
3
Recent Advances in Neonatal Diabetes.新生儿糖尿病的最新进展
Diabetes Metab Syndr Obes. 2020 Feb 12;13:355-364. doi: 10.2147/DMSO.S198932. eCollection 2020.
4
A Novel Approach to the Management of Neonatal Diabetes Using Sensor-Augmented Insulin Pump Therapy With Threshold Suspend Technology at Diagnosis.一种在诊断时使用带有阈值暂停技术的传感器增强胰岛素泵疗法治疗新生儿糖尿病的新方法。
Diabetes Spectr. 2016 Aug;29(3):176-9. doi: 10.2337/diaspect.29.3.176.
本文引用的文献
1
Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations.因Kir6.2突变导致糖尿病的患者从胰岛素转换为口服磺脲类药物治疗。
N Engl J Med. 2006 Aug 3;355(5):467-77. doi: 10.1056/NEJMoa061759.
2
Mutations in KCNJ11, which encodes Kir6.2, are a common cause of diabetes diagnosed in the first 6 months of life, with the phenotype determined by genotype.编码Kir6.2的KCNJ11基因突变是出生后6个月内诊断出的糖尿病的常见病因，其表型由基因型决定。
Diabetologia. 2006 Jun;49(6):1190-7. doi: 10.1007/s00125-006-0246-z. Epub 2006 Apr 12.
3
Glibenclamide treatment in permanent neonatal diabetes mellitus due to an activating mutation in Kir6.2.由于Kir6.2激活突变导致的永久性新生儿糖尿病中的格列本脲治疗。
J Clin Endocrinol Metab. 2004 Nov;89(11):5504-7. doi: 10.1210/jc.2004-1241.
Zotero 插件